

REGISTERED COMPANY NUMBER: 06996068 (England and Wales)
REGISTERED CHARITY NUMBER: 1132984

**REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST AUGUST 2024
FOR
THE INTERNATIONAL CML FOUNDATION**

Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

THE INTERNATIONAL CML FOUNDATION

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31ST AUGUST 2024

	Page
Report of the Trustees	1 to 4
Independent Examiner's Report	5
Statement of Financial Activities	6
Balance Sheet	7
Notes to the Financial Statements	8 to 14

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2024**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st August 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

The object of the Foundation is the advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases (together "CML") and for the purpose of carrying out those general objects, the primary objects of the Foundation are in particular:-

- (i) to improve clinical practice and disease monitoring in the treatment of CML
- (ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
- (iii) to promote and support the education of and disseminate knowledge amongst clinicians, scientists, health professionals and patients in matters concerning CML
- (iv) to promote, foster and co-ordinate collaboration that is particularly (but not exclusively) international and is not only in the areas and activities of clinical practice disease monitoring and research into CML but also in any area or activity which is or may be conducive to the acceleration of the control and/or cure of CML
- (v) to promote, set up, establish and support and share and exchange knowledge with other organisations whose objects are similar to these general or primary objects
- (vi) to assist or promote any other charitable purposes which are related to these general and primary objects.

Significant activities

In furtherance of the objects, the Foundation has the following powers:-

- (i) to promote or carry out research
- (ii) to provide advice
- (iii) to give and exchange information and advice and promote learning, study and research
- (iv) to commission, publish, distribute and contribute to papers, books, periodicals, reports, leaflets, posters and other publications of any description
- (v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
- (vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.

Public benefit

The Trustees have considered their duty to have due regard to public benefit guidance published by the Commission and in their opinion, the foregoing report on the achievements and performance demonstrates that they have complied therewith.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2024**

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The International CML Foundation (iCMLf) is a global charity working to improve the outcomes for people with chronic myeloid leukemia (CML), particularly in low- and middle-income countries (LMICs). Our mission is to foster global collaboration, share best practices, build clinical capacity, and accelerate research to ultimately find a cure for CML.

In 2023-2024, the iCMLf continued to address unmet needs in CML care and education by driving global research, enhancing medical education, and fostering access to expert guidance and clinical excellence.

SUMMARY OF CORE PROGRAMS AND IMPACT

1. Global Research

The iCMLf leads international collaborations that investigate critical questions to improve CML treatment, including:

- **Big Data Projects:** Through the Genomics Alliance and TFR (Treatment-Free Remission) Alliance, the Foundation is working to analyse over 3,400 datasets from 27 sites across 19 countries. These projects aim to understand genomic drivers of CML and improve the success rates of therapy discontinuation strategies.
- **Research Publications:** Three significant peer-reviewed studies were published this year, providing new insights into CML biology and management.

2. Education and Clinical Capacity Building

Physician education on clinical management and diagnostics remains a core focus for the iCMLf. Programs include:

- **Knowledge Centre:** Over 1,200 professionals accessed expert-led educational modules, including a new focus on fertility and pregnancy in CML.
- **Regional Discussion Groups:** Nine sessions held across three continents engaged 250 physicians from 44 countries, promoting region-specific dialogue and clinical learning.
- **Clinical Conversations and Forums:** These sessions facilitated global peer learning. Over 2,000 on-demand views were recorded across three key sessions.
- **Publications and Case discussions:** More than 8,000 views of challenging case discussions, including complex cases on pediatric relapse, pregnancy, and fourth-line therapies, provided practical guidance for clinicians.
- **In-Person Events:** iCMLf convened expert panels at major global events such as the John Goldman Conference, the American Society of Hematology meeting, and the Indian Cancer Congress.

3. Awareness, Recognition, and Advocacy

- **iCMLf Prizes:** Prestigious awards were presented to leaders in research, clinical practice, and patient advocacy.
- **Patient Support:** Programs and community engagements such as Friends of Max in India amplified patient voices and needs.

FINANCIAL REVIEW

Financial position

The financial position of the International CML Foundation remains solid.

Expenditure

- Total expenditure on programs: 67% on physician education, 11% on disease research, and 9% on patient support.
- 36% of all expenditures directly supported people with CML in LMICs.
- 13% was allocated to fundraising and 10% to governance.

Principal funding sources

The iCMLf works closely with industry and community partners to secure unrestricted grants and sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website.

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2024**

FINANCIAL REVIEW

Reserves policy

The reserves at the year end were £263,528 (2023 - £192,056). It is the policy of the Trustees to maintain sufficient reserves to ensure the day to day running of the Foundation. The level of reserves and current financial commitments are reviewed regularly at Trustees' meetings. The Foundation plans to hold a minimum of £150,000 as reserve funding. This is the amount for the foundation to operate without further income/outgoings for one year.

FUTURE PLANS

The Trustees are proud of the iCMLf's achievements in 2023-2024. Our commitment to equity in CML care, global collaboration, and scientific innovation continues to drive tangible improvements in patient outcomes. Looking ahead, the iCMLf will build on the momentum of its current programs by expanding its research networks, launching new regionally focused education initiatives, and deepening engagement with patient communities. The Foundation remains focused on supporting clinicians and researchers worldwide as we work toward a cure for CML.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

Recruitment and appointment of new trustees

The power of appointing new or additional Trustees is vested in the existing Trustees. Prior to appointment, new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.

The iCMLf Board of Directors is composed of globally renowned hematologists and researchers who provide strategic leadership to the Foundation. To ensure diverse perspectives, the Board includes representatives from low- and middle-income countries, notably Brazil and India. In 2024, the iCMLf established a Patient Advisory Committee to strengthen patient representation within its work. This new committee brings together eight CML patients and advocates from five countries, who will collaborate with the Scientific Advisory Committee to help shape and support the Foundation's mission. The iCMLf's operations are managed by a multidisciplinary team based across Australia, the United Kingdom, Germany, the United States, and India.

Organisational structure

The Chief Executive reports to the eleven iCMLf Directors, specifically the iCMLf Chairman. The iCMLf Directors are supported by an Executive Committee of 3 directors and the Chief Executive.

The operational team; Communications Director, Communications Manager, Digital Media Officer, and Program Manager, report to the Chief Executive. In June 2024 a Development Manager was hired to join the operational team.

Strategic direction, financial review and budget approval are set at an annual iCMLf Directors meeting in September/October each year. Further planning and discussion meetings are held quarterly.

Strategic planning is assisted with an annual advisor's meeting. This includes the Scientific Advisory Committee and Patient Advisory Committee. The Patient Advisors also meet quarterly.

The operational team meets quarterly. The Communications Director/Communications Manager meet biweekly with the Chief Executive respectively. The Program Manager and Development Manager meet weekly with the Chief Executive for business planning. The Chief Executive and iCMLf Chairman meet monthly.

Decisions are escalated from the operational team to the Chief Executive, iCMLf Chairman, iCMLf Executive Committee and iCMLf Board of Directors according to scale and impact.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

06996068 (England and Wales)

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST AUGUST 2024

Registered Charity number
1132984

Registered office
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

Trustees
Professor T P Hughes
Professor J Cortes Professor
Professor B Druker Professor
Professor A Hochhaus Professor
Professor J Radich Professor
Professor C Schiffer Professor
Professor J F Apperley DM FRCP/Path Professor
Professor M Mauro Professor
Professor G Saglio Professor
Dr K B B Pagnano Medical doctor (appointed 1/10/2023)
Dr H Malhotra Medical doctor (appointed 1/10/2023)

Company Secretary
Ms N C Evans

Independent Examiner
R Appleyard FCA
Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

Bankers
HSBC Bank, 152 Portobello Road, London, W11 2EA

QUALIFYING THIRD PARTY INDEMNITY PROVISION

There is a qualifying third party indemnity in force at the date of approval of this report, for the benefit of every director or other officer or auditor.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

30/05/2025
Approved by order of the board of trustees on and signed on its behalf
by:

.....
Professor J Cortes - Trustee

Independent examiner's report to the trustees of The International CML Foundation ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st August 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

R Appleyard FCA
The Institute of Chartered Accountants in England and Wales

Gibbons Mannington & Phipps LLP
Chartered Accountants
20 Eversley Road
Bexhill-on-Sea
East Sussex
TN40 1HE

Date:30 May 2025.....

THE INTERNATIONAL CML FOUNDATION

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31ST AUGUST 2024**

	Notes	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		104,927	214,267	319,194	107,364
Other income	2	(8,700)	-	(8,700)	(17,489)
Total		96,227	214,267	310,494	89,875
EXPENDITURE ON					
Charitable activities					
Preceptorships		3,808	-	3,808	-
Diagnostics program		-	11,841	11,841	5,328
Scientific meetings		31,833	-	31,833	43,734
Clinical and Scientific communication		35,060	31,097	66,157	17,799
Fundraising		25,784	-	25,784	21,949
Cure Consortium		-	1,820	1,820	-
Covid-19 & CML Study		1,750	-	1,750	2,722
Knowledge Centre		3,675	-	3,675	46,023
Clinical Conversations program		11,585	-	11,585	9,175
Research		-	-	-	3,552
RDG		17,160	15,549	32,709	18,630
Alliances		-	11,103	11,103	13,608
Education meetings		1,554	20,405	21,959	-
Other		14,998	-	14,998	43,839
Total		147,207	91,815	239,022	226,359
NET INCOME/(EXPENDITURE)		(50,980)	122,452	71,472	(136,484)
RECONCILIATION OF FUNDS					
Total funds brought forward		81,912	110,144	192,056	328,540
TOTAL FUNDS CARRIED FORWARD		30,932	232,596	263,528	192,056

The notes form part of these financial statements

BALANCE SHEET
31ST AUGUST 2024

	Notes	Unrestricted funds £	Restricted funds £	2024 Total funds £	2023 Total funds £
CURRENT ASSETS					
Debtors	9	36,315	15,317	51,632	113,534
Cash at bank and in hand		1,398	217,278	218,676	85,374
		37,713	232,595	270,308	198,908
CREDITORS					
Amounts falling due within one year	10	(6,780)	-	(6,780)	(6,852)
NET CURRENT ASSETS		30,933	232,595	263,528	192,056
TOTAL ASSETS LESS CURRENT LIABILITIES		30,933	232,595	263,528	192,056
NET ASSETS		30,933	232,595	263,528	192,056
FUNDS	11				
Unrestricted funds				30,933	81,912
Restricted funds				232,595	110,144
TOTAL FUNDS				263,528	192,056

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on ...30/05/2025..... and were signed on its behalf by:

.....
J Cortes - Trustee

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

Items of income are recognised and included in the accounts when all of the following criteria are met:

- The charity or its subsidiary have entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Debtors

Debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid after taking account of any trade discounts due.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result and are shown as other income.

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2024

2. OTHER INCOME

Other income consists of the profit/loss on foreign currency exchange in accordance with the accounting policy on foreign exchange transactions.

3. SUPPORT COSTS

	Management fees £	Finance £	Other £	Governance costs £	Totals £
Other resources expended	8,710	363	1,329	4,596	14,998
Preceptorships	-	17	-	-	17
Diagnostics program	11,841	-	-	-	11,841
Scientific meetings	30,221	-	-	-	30,221
Clinical and Scientific communication	58,490	-	-	-	58,490
Fundraising	21,983	147	1,944	-	24,074
Cure Consortium	1,820	-	-	-	1,820
Covid-19 & CML Study	1,750	-	-	-	1,750
Knowledge Centre	3,675	-	-	-	3,675
Clinical Conversations program	11,585	-	-	-	11,585
RDG	31,124	18	-	-	31,142
Alliances	11,103	-	-	-	11,103
	<u>192,302</u>	<u>545</u>	<u>3,273</u>	<u>4,596</u>	<u>200,716</u>

Support costs, included in the above, are as follows:

Management fees

	Other resources expended £	Diagnostics program £	Scientific meetings £	Clinical and Scientific communica £
Management & admin	<u>8,710</u>	<u>11,841</u>	<u>30,221</u>	<u>58,490</u>
			Covid-19 & CML Study £	Knowledge Centre £
Management & admin	<u>21,983</u>	<u>1,820</u>	<u>1,750</u>	<u>3,675</u>
			2024	2023
	Clinical Conversations program £	RDG £	Alliances £	Total activities £
Management & admin	<u>11,585</u>	<u>31,124</u>	<u>11,103</u>	<u>170,093</u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2024

3. SUPPORT COSTS - continued
Finance

	Other resources expended £	Preceptorships £	Fundraising £
Bank charges	<u>363</u>	<u>17</u>	<u>147</u>
		2024 Total activities	2023 Total activities
Bank charges	<u>RDG £ 18</u>	<u>£ 545</u>	<u>£ 507</u>
Other		2024	2023
	Other resources expended £	Total activities £	Total activities £
Sundry office costs	<u>1,329</u>	<u>3,273</u>	<u>2,889</u>
Governance costs		2024	2023
		Other resources expended £	Total activities £
Accountancy - Independent examination fee		<u>4,596</u>	<u>4,584</u>

4. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2024 £	2023 £
Accountancy - Independent examination fee	<u>4,596</u>	<u>4,584</u>

5. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31st August 2024 nor for the year ended 31st August 2023.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31st August 2024 nor for the year ended 31st August 2023.

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2024

6. STAFF COSTS

The average monthly number of employees during the year was as follows:

	2024	2023
	6	5
Charitable activities	<u>6</u>	<u>5</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2024	2023
	1	-
£80,001 - £90,000	<u>1</u>	<u>-</u>
£90,001 - £100,000	<u>-</u>	<u>1</u>
	<u>1</u>	<u>1</u>

7. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	82,599	24,765	107,364
Other income	(17,489)	-	(17,489)
Total	<u>65,110</u>	<u>24,765</u>	<u>89,875</u>
EXPENDITURE ON			
Charitable activities			
Diagnostics program	-	5,328	5,328
Scientific meetings	43,734	-	43,734
Clinical and Scientific communication	13,696	4,103	17,799
Fundraising	21,949	-	21,949
Covid-19 & CML Study	2,722	-	2,722
Knowledge Centre	41,118	4,905	46,023
Clinical Conversations program	9,175	-	9,175
Research	3,552	-	3,552
RDG	18,630	-	18,630
Alliances	-	13,608	13,608
Other	40,631	3,208	43,839
Total	<u>195,207</u>	<u>31,152</u>	<u>226,359</u>
NET INCOME/(EXPENDITURE)	(130,097)	(6,387)	(136,484)
RECONCILIATION OF FUNDS			
Total funds brought forward	212,009	116,531	328,540
TOTAL FUNDS CARRIED FORWARD	<u><u>81,912</u></u>	<u><u>110,144</u></u>	<u><u>192,056</u></u>

8. VOLUNTEERS

The charity heavily relies upon the many medical professionals who donate their time to help run the various charitable activities undertaken. It is not possible to accurately calculate the value of the services contributed by these volunteers and therefore the numbers do not reflect either the income or expenditure, however it is thought to be in the region of £230,000.

9. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Other debtors	51,632	113,534

Included within other debtors is a balance of £49,997 (2023 - £103,109) in respect of funds held by Paypal.

10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Trade creditors	-	2,268
Accrued expenses	6,780	4,584
	6,780	6,852

11. MOVEMENT IN FUNDS

	At 1/9/23 £	Net movement in funds £	At 31/8/24 £
Unrestricted funds			
General fund	81,912	(50,979)	30,933
Restricted funds			
Novartis Pharmaceuticals Corporation	103,090	(11,840)	91,250
Pfizer Grant	7,054	(7,054)	-
Incyte - Alliance/Cure Programs	-	111,218	111,218
Patient Education	-	30,127	30,127
	110,144	122,451	232,595
TOTAL FUNDS	192,056	71,472	263,528

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2024

11. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	96,227	(147,206)	(50,979)
Restricted funds			
Novartis Pharmaceuticals Corporation	1	(11,841)	(11,840)
Takeda Oncology	31,097	(31,097)	-
Pfizer Grant	-	(7,054)	(7,054)
Incyte - Alliance/Cure Programs	117,088	(5,870)	111,218
Patient Education	50,532	(20,405)	30,127
Novartis RDG	15,549	(15,549)	-
	<u>214,267</u>	<u>(91,816)</u>	<u>122,451</u>
TOTAL FUNDS	<u>310,494</u>	<u>(239,022)</u>	<u>71,472</u>

Comparatives for movement in funds

	At 1/9/22 £	Net movement in funds £	At 31/8/23 £
Unrestricted funds			
General fund	212,009	(130,097)	81,912
Restricted funds			
Novartis Pharmaceuticals Corporation	111,626	(8,536)	103,090
Novartis Pharma AG	4,905	(4,905)	-
Pfizer Grant	-	7,054	7,054
	<u>116,531</u>	<u>(6,387)</u>	<u>110,144</u>
TOTAL FUNDS	<u>328,540</u>	<u>(136,484)</u>	<u>192,056</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	65,110	(195,207)	(130,097)
Restricted funds			
Novartis Pharmaceuticals Corporation	-	(8,536)	(8,536)
Novartis Patient	4,103	(4,103)	-
Novartis Pharma AG	-	(4,905)	(4,905)
Pfizer Grant	20,662	(13,608)	7,054
	<u>24,765</u>	<u>(31,152)</u>	<u>(6,387)</u>
TOTAL FUNDS	<u>89,875</u>	<u>(226,359)</u>	<u>(136,484)</u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST AUGUST 2024

11. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/9/22 £	Net movement in funds £	At 31/8/24 £
Unrestricted funds			
General fund	212,009	(181,076)	30,933
Restricted funds			
Novartis Pharmaceuticals Corporation	111,626	(20,376)	91,250
Novartis Pharma AG	4,905	(4,905)	-
Incyte - Alliance/Cure Programs	-	111,218	111,218
Patient Education	-	30,127	30,127
	<u>116,531</u>	<u>116,064</u>	<u>232,595</u>
TOTAL FUNDS	<u>328,540</u>	<u>(65,012)</u>	<u>263,528</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	161,337	(342,413)	(181,076)
Restricted funds			
Novartis Pharmaceuticals Corporation	1	(20,377)	(20,376)
Takeda Oncology	31,097	(31,097)	-
Novartis Patient	4,103	(4,103)	-
Novartis Pharma AG	-	(4,905)	(4,905)
Pfizer Grant	20,662	(20,662)	-
Incyte - Alliance/Cure Programs	117,088	(5,870)	111,218
Patient Education	50,532	(20,405)	30,127
Novartis RDG	15,549	(15,549)	-
	<u>239,032</u>	<u>(122,968)</u>	<u>116,064</u>
TOTAL FUNDS	<u>400,369</u>	<u>(465,381)</u>	<u>(65,012)</u>

12. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st August 2024.